Pathogenesis of Chagas disease: Time to move on

Fabiana S. Machado, Kevin M. Tyler, Fatima Brant, Lisia Esper, Mauro M. Teixeira, Herbert B. Tanowitz

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Trypanosoma cruzi is the etiologic agent of Chagas disease. The contributions of parasite and immune system for disease pathogenesis remain unresolved and controversial. The possibility that Chagas disease was an autoimmune progression triggered by T. cruzi infection led some to question the benefit of treating chronically T. cruzi-infected persons with drugs. Furthermore, it provided the rationale for not investing in research aimed at a vaccine which might carry a risk of inducing autoimmunity or exacerbating inflammation. This viewpoint was adopted by cash-strapped health systems in the developing economies where the disease is endemic and has been repeatedly challenged by researchers and clinicians in recent years and there is now a considerable body of evidence and broad consensus that parasite persistence is requisite for pathogenesis and that antiparasitic immunity can be protective against T. cruzi pathogenesis without eliciting autoimmune pathology. Thus, treatment of chronically infected patients is likely to yield positive outcomes and efforts to understand immunity and vaccine development should be recognized as a priority area of research for Chagas disease.

Original languageEnglish (US)
Pages (from-to)1743-1758
Number of pages16
JournalFrontiers in Bioscience - Elite
Volume4 E
Issue number5
StatePublished - Jan 1 2012

Fingerprint

Chagas Disease
Trypanosoma cruzi
Immunity
Parasites
Vaccines
Antiparasitic Agents
Endemic Diseases
Immune System Diseases
Autoimmunity
Research
Immune system
Pathology
Research Personnel
Inflammation
Health
Infection
Pharmaceutical Preparations
Therapeutics

Keywords

  • Autoimmunity
  • Cardiac disease
  • Chagas disease
  • Chemokines
  • Cytokines
  • Immunity
  • Inflammation
  • Myocardial inflammation
  • Review
  • Toll-like receptors
  • Trypanosoma cruzi

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Medicine(all)

Cite this

Machado, F. S., Tyler, K. M., Brant, F., Esper, L., Teixeira, M. M., & Tanowitz, H. B. (2012). Pathogenesis of Chagas disease: Time to move on. Frontiers in Bioscience - Elite, 4 E(5), 1743-1758.

Pathogenesis of Chagas disease : Time to move on. / Machado, Fabiana S.; Tyler, Kevin M.; Brant, Fatima; Esper, Lisia; Teixeira, Mauro M.; Tanowitz, Herbert B.

In: Frontiers in Bioscience - Elite, Vol. 4 E, No. 5, 01.01.2012, p. 1743-1758.

Research output: Contribution to journalArticle

Machado, FS, Tyler, KM, Brant, F, Esper, L, Teixeira, MM & Tanowitz, HB 2012, 'Pathogenesis of Chagas disease: Time to move on', Frontiers in Bioscience - Elite, vol. 4 E, no. 5, pp. 1743-1758.
Machado FS, Tyler KM, Brant F, Esper L, Teixeira MM, Tanowitz HB. Pathogenesis of Chagas disease: Time to move on. Frontiers in Bioscience - Elite. 2012 Jan 1;4 E(5):1743-1758.
Machado, Fabiana S. ; Tyler, Kevin M. ; Brant, Fatima ; Esper, Lisia ; Teixeira, Mauro M. ; Tanowitz, Herbert B. / Pathogenesis of Chagas disease : Time to move on. In: Frontiers in Bioscience - Elite. 2012 ; Vol. 4 E, No. 5. pp. 1743-1758.
@article{217571a870ad4f958c88511485879e51,
title = "Pathogenesis of Chagas disease: Time to move on",
abstract = "Trypanosoma cruzi is the etiologic agent of Chagas disease. The contributions of parasite and immune system for disease pathogenesis remain unresolved and controversial. The possibility that Chagas disease was an autoimmune progression triggered by T. cruzi infection led some to question the benefit of treating chronically T. cruzi-infected persons with drugs. Furthermore, it provided the rationale for not investing in research aimed at a vaccine which might carry a risk of inducing autoimmunity or exacerbating inflammation. This viewpoint was adopted by cash-strapped health systems in the developing economies where the disease is endemic and has been repeatedly challenged by researchers and clinicians in recent years and there is now a considerable body of evidence and broad consensus that parasite persistence is requisite for pathogenesis and that antiparasitic immunity can be protective against T. cruzi pathogenesis without eliciting autoimmune pathology. Thus, treatment of chronically infected patients is likely to yield positive outcomes and efforts to understand immunity and vaccine development should be recognized as a priority area of research for Chagas disease.",
keywords = "Autoimmunity, Cardiac disease, Chagas disease, Chemokines, Cytokines, Immunity, Inflammation, Myocardial inflammation, Review, Toll-like receptors, Trypanosoma cruzi",
author = "Machado, {Fabiana S.} and Tyler, {Kevin M.} and Fatima Brant and Lisia Esper and Teixeira, {Mauro M.} and Tanowitz, {Herbert B.}",
year = "2012",
month = "1",
day = "1",
language = "English (US)",
volume = "4 E",
pages = "1743--1758",
journal = "Frontiers in Bioscience - Elite",
issn = "1945-0494",
publisher = "Frontiers in Bioscience",
number = "5",

}

TY - JOUR

T1 - Pathogenesis of Chagas disease

T2 - Time to move on

AU - Machado, Fabiana S.

AU - Tyler, Kevin M.

AU - Brant, Fatima

AU - Esper, Lisia

AU - Teixeira, Mauro M.

AU - Tanowitz, Herbert B.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Trypanosoma cruzi is the etiologic agent of Chagas disease. The contributions of parasite and immune system for disease pathogenesis remain unresolved and controversial. The possibility that Chagas disease was an autoimmune progression triggered by T. cruzi infection led some to question the benefit of treating chronically T. cruzi-infected persons with drugs. Furthermore, it provided the rationale for not investing in research aimed at a vaccine which might carry a risk of inducing autoimmunity or exacerbating inflammation. This viewpoint was adopted by cash-strapped health systems in the developing economies where the disease is endemic and has been repeatedly challenged by researchers and clinicians in recent years and there is now a considerable body of evidence and broad consensus that parasite persistence is requisite for pathogenesis and that antiparasitic immunity can be protective against T. cruzi pathogenesis without eliciting autoimmune pathology. Thus, treatment of chronically infected patients is likely to yield positive outcomes and efforts to understand immunity and vaccine development should be recognized as a priority area of research for Chagas disease.

AB - Trypanosoma cruzi is the etiologic agent of Chagas disease. The contributions of parasite and immune system for disease pathogenesis remain unresolved and controversial. The possibility that Chagas disease was an autoimmune progression triggered by T. cruzi infection led some to question the benefit of treating chronically T. cruzi-infected persons with drugs. Furthermore, it provided the rationale for not investing in research aimed at a vaccine which might carry a risk of inducing autoimmunity or exacerbating inflammation. This viewpoint was adopted by cash-strapped health systems in the developing economies where the disease is endemic and has been repeatedly challenged by researchers and clinicians in recent years and there is now a considerable body of evidence and broad consensus that parasite persistence is requisite for pathogenesis and that antiparasitic immunity can be protective against T. cruzi pathogenesis without eliciting autoimmune pathology. Thus, treatment of chronically infected patients is likely to yield positive outcomes and efforts to understand immunity and vaccine development should be recognized as a priority area of research for Chagas disease.

KW - Autoimmunity

KW - Cardiac disease

KW - Chagas disease

KW - Chemokines

KW - Cytokines

KW - Immunity

KW - Inflammation

KW - Myocardial inflammation

KW - Review

KW - Toll-like receptors

KW - Trypanosoma cruzi

UR - http://www.scopus.com/inward/record.url?scp=84860872150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860872150&partnerID=8YFLogxK

M3 - Article

C2 - 22201990

AN - SCOPUS:84860872150

VL - 4 E

SP - 1743

EP - 1758

JO - Frontiers in Bioscience - Elite

JF - Frontiers in Bioscience - Elite

SN - 1945-0494

IS - 5

ER -